August 7, 2025Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.44. Operator: Good morning. My name is John, and I'll be your conference ...

Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential ...

Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug ...

Mallinckrodt plc today announced the appointment of Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025. Ms. Stamoulis, currently the EVP and Chief Financial ...

Drugmakers Mallinckrodt and Endo have today completed their near $7 billion merger deal, which was first announced in March.

Highly Complementary Companies to Advance Therapies to Address Unmet Patient Needs Respective Generics Businesses and Endo's Sterile Injectables Business ...

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that it will host an investor event at the Endocrine Society’s annual meeting (ENDO 2025) on ...

Mallinckrodt announced that the Irish High Court has given the necessary ruling to enable its combination with Endo, advancing the companies' plan to merge in a stock and cash transaction that will ...

Endo, Inc. (OTCQX: NDOI) announced today that three presentations related to plantar fibromatosis (PFI) and plantar fasciitis ...

Hopes have been fuelled that the UK pharma industry can escape US tariffs as Keir Starmer prepares for talks with Donald Trump. The PM is expected to meet the President in Scotland next week ...

Natco Pharma offers to buy 35.75% stake in South Africa's Adcock Ingram for Rs 2,000 crore Natco Pharma to set up arm in South Africa with investment of Rs 2,100 crore ...